ABSTRACT: Spontaneously hypertensive rats (SHR) are characterized by impaired erectile function and overactivity of the procontractile RhoA/Rho-associated, coiled-coil-containing protein kinase (RhoA/ROCK) pathway, as compared with their normotensive counterpart, Wistar-Kyoto rats. By measuring the intracavernous pressure:mean arterial pressure (ICP:MAP) ratio after electrostimulation of the cavernous nerve, we confirmed these findings and showed that responsiveness to sildenafil (25 mg/kg by oral gavage) also is hampered in SHR. A 2-week treatment with atorvastatin (5 and 30 mg/kg) improved the sildenafil-induced ICP:MAP increase and normalized RhoA and ROCK2 overexpression in SHR corpora cavernosa (CC). Conversely, other genes, neuronal nitric oxide synthase (NOS), endothelial NOS, and phosphodiesterase 5, were unaffected. In human fetal smooth muscle cells derived from CC (hfPSMC), atorvastatin inhibited RhoA membrane translocation and ROCK activity, as well as RhoA-dependent biologic functions like cell migration and cell proliferation. Atorvastatin's effect on migration was rescued in a dose-dependent manner by geranylgeranyl pyrophosphate, suggesting the involvement of RhoA geranylgeranylation. In hfPSMC, atorvastatin decreased the expression of RhoA-dependent genes such as ROCK2, desmin, a-smooth muscle actin, SM22a, and myocardin. In contrast to atorvastatin, elocalcitol, a vitamin D analog that also interferes with RhoA activation in SHR bladder, was unable to restore penile responsiveness to sildenafil. In conclusion, atorvastatin, but not elocalcitol, ameliorates sildenafil-induced penile erections in SHR, likely by interfering with RhoA/ROCK signaling within the penis.
S everal contractile systems are responsible for maintaining the penis in the contracted/flaccid state, its predominant physiologic condition. The most characterized ones are endothelin 1 (ET1) and noradrenaline (NA), which mediate their effects via a receptor-coupled intracellular calcium rise (Maggi et al, 2000; . Although this receptor-mediated intracellular calcium increase is transient, penile smooth muscle (SM) cells are able to maintain the contracted state thereafter via a calcium-sensitizing pathway. This pathway consists of the activation of parallel pathways able to increase calcium sensitivity even at the same intracellular calcium levels , and a primary mechanism involves the RhoA/Rho kinase pathway (Wang et al, 2002) . Accordingly, the selective inhibitor of Rho kinase activity, Y-27632, has been shown to cause relaxation of human corpora cavernosa (CC) in vitro and to induce penile erection in animal models ). Moreover, transfection of a RhoA dominant negative mutant was found to enhance erectile function in rats (Bivalacqua et al, 2004) . Hence, prevention of RhoA activation could ameliorate penile erection, whereas enhancement of RhoA activity appears to mediate erectile dysfunction (ED).
RhoA is a member of a small monomeric GTPase family that is involved in SM contraction and the regulation of several other SM-dependent processes such as cell adhesion (Ren et al, 1999) , motility (Wheeler 5 These authors contributed equally to the article.
and Ridley, 2004) , migration (Wheeler and Ridley, 2004) , and proliferation (Aznar and Lacal, 2001) . As soon as ET1 and NA bind to their excitatory receptors, RhoA is converted from the cytoplasmic, inactive GDPbound form into an active GTP-bound complex that translocates to the plasma membrane, where it binds via geranylgeranylation, initiating signal transduction. The best-characterized downstream effectors of RhoA are Rho-associated, coiled-coil-containing protein kinases (ROCKs), which are directly involved in SM contraction (Noma et al, 2006) . The 2 described ROCK isoforms (ROCK1 or ROKb and ROCK2 or ROKa), sharing 65% homology in amino acid sequence and 92% homology in their kinase domains, are serine-threonine kinases that are able to maintain the phosphorylated state of the myosin light chain and thus the contractile tone independently of intracellular calcium levels. More recently the RhoA/ROCK pathway has been involved in the ''excitation-transcription coupling'' of SM cells (Barlow et al, 2006) . RhoA/ROCK signaling stimulates the transcription of SM-specific genes, such as a-SM actin (a-SMA), SM myosin heavy chain, and desmin, through the induction of myocardin, a transcriptional coactivator controlling several genes involved in SM commitment and function (Wamhoff et al, 2004; Pipes et al, 2006) .
RhoA/ROCK pathway overactivity has been shown to be involved in several pathophysiologic processes such as angiogenesis, atherosclerosis, cerebral and coronary vasospasm, cerebral ischemia, glomerulosclerosis, hypertension, myocardial hypertrophy, myocardial ischemia-reperfusion injury, neointima formation, pulmonary hypertension, vascular remodeling, diabetes mellitus, and ED (Chrissobolis and Sobey, 2006; Jin and Burnett, 2006; Moore and Wang, 2006; Noma et al, 2006; Calò and Pessina, 2007) . ED is often associated with hypertension (Billups et al, 2005; Mulhall et al, 2006) , and both conditions might share similar pathogenetic determinants. A longitudinal study in spontaneously hypertensive rats (SHR) clearly showed that changes in erectile tissue precede aortic ones (Behr-Roussel et al, 2006) , as suggested also in humans (Billups et al, 2005; Montorsi et al, 2006) . RhoA is overactive and hypersensitive to G protein-coupled receptor stimulation in several SHR tissues, including vascular SM cells (Moriki et al, 2004; Ying et al, 2004) , brainstem (Sagara et al, 2007) , and preglomerular microvascular SM cells (Jackson et al, 2005) . It has been postulated that RhoA overactivity significantly contributes to the development of hypertension in this rat strain. A similar finding was also reported in the penis (Wilkes et al, 2004) , where the up-regulation of RhoA/ROCK signaling is considered to play an important role in hypertension-associated ED Wilkes et al, 2004) . Accordingly, Y-27632 administration partially restores erectile function (Wilkes et al, 2004) and synergizes with phosphodiesterase 5 (PDE5) inhibition through zaprinast .
The recent introduction of the PDE5 inhibitor sildenafil has greatly improved the success rate of ED treatment; however, hypertensive patients are usually less responsive to sildenafil than normotensive ones (Chia et al, 2004) . The aim of this study was to systematically investigate the in vivo effects in SHR compared with their normotensive counterpart, WistarKyoto (WKY) rats, sildenafil treatment as monotherapy or in combination with atorvastatin, a drug known to interfere with the RhoA/ROCK pathway by decreasing RhoA geranylgeranylation (Bonetti et al, 2003; Rikitake and Liao, 2005) . The effects of atorvastatin were compared with those obtained with elocalcitol (also known as BXL-628), a nonhypercalcemic vitamin D analog that has been recently demonstrated to interfere with RhoA activation in SHR bladder, characterized by RhoA/ROCK overactivity (Morelli et al, 2007) . The mechanism by which atorvastatin is able to interfere with RhoA activity has been studied using a previously characterized cellular model of human penile SM cells (hfPSMC; Granchi et al, 2002; Crescioli et al, 2003b; Filippi et al, 2003a,b; Vignozzi et al, 2005) .
Methods

In Vivo Studies on Erectile Function
Male SHR (10 and 12 weeks; Charles River Laboratories, Calco, Italy) were treated by oral gavage with atorvastatin (a group with 5 and another group with 30 mg/kg/d for 2 weeks; LKT Laboratories Inc, St Paul, Minn) or a fixed dose of elocalcitol (30 mg/kg/ d for 5 days of the first week and 4 days of the second week for a total of 9 administrations; Bioxell, Milan, Italy), as previously described . Male WKY rats (12 weeks; Charles River Laboratories) were used as normotensive controls. One hour before experiment initiation, rats were treated with sildenafil (25 mg/kg; Pfizer Italia, Rome, Italy) by oral gavage. Rats were anesthetized intraperitoneally with sodium pentobarbital (45 mg/kg; Abbott SpA, Campoverde d'Aprilia, Italy). Mean arterial pressure (MAP) was continuously monitored via the femoral artery. Both crura were exposed, and each was perforated with a 26-gauge needle connected to PE-50 tubing for intracavernous pressure (ICP) recordings. MAP and ICP were recorded via a pressure transducer (World Precision Instruments Inc, Sarasota, Fla) connected to a recorder (TA240; Gold Inc, Cleveland, Ohio). For electrostimulation (ES), a bipolar platinum electrode attached to an ST6 stimulator (Biomedica Mangoni Inc, Pisa, Italy) was mounted on the cavernous nerve (CN). ES (width, 5 ms; duration, 30 seconds; 2.5 V) at different frequencies (1, 2, 4, 8, 16 , and 32 Hz) was performed. The erectile response elicited by ES was quantified by calculating max ICP:MAP 6 100, as previously described (Zhang et al, 2006) .
Rat Tissues
Rats were sacrificed by cervical dislocation. Urinary bladders and CC were removed and immediately frozen in liquid nitrogen at 280uC until RNA preparation. Experiments were performed in accordance to the Italian Ministerial Law 116/92 and approved by the Institutional Animal Care and Use Committee of the University of Florence, Florence, Italy.
Cholesterol and Calcium Measurements
Blood samples for total cholesterol measurements were obtained at baseline via the femoral veins. The blood was immediately centrifuged at 10006g for 20 minutes, and the plasma was stored at 220uC until analyzed. Plasma cholesterol levels were measured with an automated system (Abbott Diagnostics, Abbott Park, Ill). Serum calcium levels were measured with a commercially available colorimetric assay (Sigma-Aldrich, St Louis, Mo) according to the manufacturer's instructions and as previously reported .
Human Tissues
Human tissues (testis, epididymis, CC, prostate, bladder, heart, brain, and skeletal muscle) were collected during surgery for benign diseases. All tissue samples were obtained after the approval of the Hospital Committee for Investigation in Humans (protocol 6783-04; Azienda Ospedaliera Universitaria Careggi, Florence, Italy) and after receiving consent from the informed patients. Immediately after removal, tissue samples were shock-frozen in liquid nitrogen and stored at 280uC until RNA preparation.
CC Cell Cultures
hfPSMC were prepared from 7 samples of fetal male external genitalia (11-12 weeks of gestation) obtained after spontaneous or therapeutic abortion, as previously described (Granchi et al, 2002; Crescioli et al, 2003a; Filippi et al, 2003a,b; Vignozzi et al, 2005) . The experiments were performed using hfPSMC from the seventh to the 13th passage in Dulbecco modified Eagle medium supplemented with 5 mM glucose and Ham F12 medium.
Confocal Laser Microscopy
hfPSMC were seeded in growth medium onto sterile glass slides (approximately 10 4 cells/mL) and incubated for 48 hours with ET1 (100 nM; Calbiochem, San Diego, Calif), atorvastatin (1 mM), or ET1 (100 nM) in combination with atorvastatin (1 mM). Cells in serum-free growth medium were used as controls. Cells were then fixed with 3.7% paraformaldehyde (pH 7.4) for 10 minutes, permeabilized for 10 minutes with phosphate-buffered saline (PBS) containing 0.1% Triton X-100, and incubated with 2% bovine serum albumin (BSA) for 15 minutes. Immunostaining was performed as previously described (Morelli et al, 2007) Subconfluent hfPSMC were incubated for 24 hours in serum-free medium before exposure to the following 48-hour treatments: ET1 (100 nM) in the absence or presence of atorvastatin (1 mM) and atorvastatin alone (1 mM) or in combination with geranylgeranyl pyrophosphate (GGPP; 1 mM; Sigma-Aldrich) added 6 hours before cells were collected. Cells were collected using trypsin-EDTA and were divided into 2 aliquots: one for total protein extraction and the other for membrane/cytosolic preparations. Membrane and cytosolic fractions were prepared using the ProteoExtract subcellular proteome extraction kit (Calbiochem) according to the manufacturer's instructions. Protein extracts were quantified with the BCA reagent (Pierce, Rockford, Ill). Equal volumes of samples (15 mg) were resolved by 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis. Western blot analysis with an anti-RhoA antibody (1:500; Santa Cruz Biotechnology) was performed as previously described (Morelli et al, 2007) . Equal protein loading was verified by Ponceau-S staining (Sigma-Aldrich). Densitometric analysis of band intensity acquired by a plot bed scanner (IS440CF; Kodak Digital Science, Cinisello Balsamo, Italy) was performed using Photoshop 5.5 software (Adobe Systems Inc Italia srl, Agrate Brianza, Italy).
ROCK Activity Assay
After serum deprivation for 24 hours, hfPSMC were stimulated for 48 hours with ET1 (100 nM; Calbiochem) in the absence or presence of atorvastatin (1 mM). Cells in serum-free growth medium were used as controls. Cells were harvested by rubber policeman using lysis buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 1 mM EGTA, 0.4 mM paraphenyl methane sulphonyl fluoride, 1 mg/mL pepstatin, 0.5 mg/mL leupeptin, 2 mM NaF, 2 mM Na 3 VO 4 ). Cells were lysed by 3 cycles of sonication. Protein extracts were quantified with the BCA reagent (Pierce). Samples were prepared for the kinase assay by immunoprecipitating equal amounts of cell lysate with an anti-ROCK antibody (SC17794; Santa Cruz Biotechnology), as previously described (Morelli et al, 2007) . The immunokinase assay was carried out using the CycLex Rho-kinase Assay kit (MBL International, Way Woburn, Mass) following the manufacturer's instructions.
Cell Proliferation Assay
hfPSMC (2.3 x 10 4 ) were seeded into 12-well plates in growth medium. After 24 hours, the cells were washed in PBS and incubated overnight in phenol red and serum-free medium containing 0.1% BSA. In the first set of experiments, increasing concentrations of atorvastatin (10 nM-100 mM) or elocalcitol (10 pM-100 nM) were added for 48 hours together with a fixed concentration of platelet-derived growth factor BB (PDGF-BB; 25 ng/mL; Sigma-Aldrich). In a second set of experiments, the effect of atorvastatin (1 mM) on PDGF-BBinduced cell growth was tested in the presence or absence of the selective RhoA inhibitor C3 exoenzyme (1 mg/mL; Calbiochem), guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 1 mM; Tocris, Bristol, United Kingdom), or nitric oxide inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 1 mM; Sigma-Aldrich). In all experiments, PDGF-BB (25 ng/mL) was also tested alone, and untreated cells in serum-free growth medium were used as controls. After 48 hours, cells were trypsinized, and the proliferation rate was derived by hemocytometer counting of 9 different fields for each well. Each experimental point was repeated at least in triplicate in at least 3 different experiments. Results are expressed as the percent variation (mean 6 SEM) over PDGF-BB or basal conditions.
Cell Chemotaxis Assay
The effect of increasing concentrations of elocalcitol (10 pM-100 nM) or atorvastatin (10 nM-100 mM) on ET1-induced hfPSMC migration was studied in a P48 multiwell Boyden chamber (Nuclepore Inc, Pleasanton, Calif). Chemotaxis was evaluated as previously described Morelli et al, 2007 ) using polyvinyl-pyrrolidine-free polycarbonate filters with an 8-mm pore size coated with 20 mg/mL type I collagen (BD Biosciences, Bedford, Mass). ET1 (100 nM in 28 mL) was added to the lower wells, and cells (1 6 10 4 cells in 40 mL) were seeded into the upper wells of the chamber with or without elocalcitol or atorvastatin and incubated at 37uC for 5 hours. The effects of atorvastatin (1 mM) in the presence of increasing concentrations (10 nM-1 mM) of GGPP (Sigma-Aldrich) or elocalcitol (10 nM) in the presence of 1 mM GGPP were also tested on ET1-induced (100 nM) cell migration. Unstimulated cells in serumfree culture medium were used as controls of basal migration. The inhibitory effect on ET1-induced migration was tested using methanol-fixed cells stained with Diff-Quick (DADE Behring AG, Dü dingen, Switzerland), and cell migration was measured by microscopic evaluation of the number of cells that moved across the filter into 10 random fields. Each experimental point was replicated at least 5 times. Results were obtained from 3 independent experiments. Data are expressed as mean 6 SEM of the percentage increase with ET1-induced migration or basal conditions as 100%.
Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction
Isolation of RNA from rat and human tissues and hfPSMC cells was performed using the RNAeasy kit (QIAGEN, Valencia, Calif). cDNA synthesis was performed as previously described (Morelli et al, 2007) . mRNA quantitative analysis was performed according to the fluorescent TaqMan methodology (Morelli et al, 2004; Morelli et al, 2007) . Polymerase chain reaction (PCR) primers and probes specific for mRNA sequences of target genes (RhoA, ROCK1, ROCK2, endothelial nitric oxide synthase [eNOS], neuronal NOS [nNOS], PDE5, vitamin D receptor [VDR] , desmin, a-SMA, transgelin or SM22a, and myocardin) were purchased from Applied Biosystems (Foster City, Calif). b 2 -microglobulin and 18S rRNA were chosen as reference genes for rat and human samples, respectively, and were selected among the endogenous controls provided by Applied Biosystems. The PCR mixture (25-ml final volume) consisted of 1X final concentrations of primers and probe mix, 1X final concentration of a universal PCR master mix (Applied Biosystems), and 25 ng of cDNA. Amplification and detection were performed with the ABI Prism 7700 Sequence Detection System, as previously reported (Morelli et al, 2007) . Each measurement was carried out in duplicate. Data analysis was based on the comparative Ct method according to the manufacturer's instructions (Applied Biosystems).
Statistical Analysis
Results are expressed as mean 6 SEM for n experiments. Statistical analysis was performed with 1-way analysis of variance test followed by Tukey-Kramer post hoc analysis, and P , .05 was considered significant. Half-maximal response effective dose (ED 50 ) and halfmaximal response inhibitory concentration (IC 50 ) values were calculated using the computer program ALLFIT (De Lean et al, 1978) .
Results
Effect of Atorvastatin and Elocalcitol on In Vivo Erectile Function
The effects of atorvastatin and elocalcitol on erectile function in vivo, as elicited by ES of the CN in the presence or absence of sildenafil, are shown in Figure 1 . A frequency-dependent increase in the ICP:MAP ratio was observed in all experimental groups, without statistically significant differences in ED 50 among groups (shared ED 50 5 2.81 6 0.26 Hz; P 5 .11). In the absence of sildenafil, the ICP:MAP ratio was significantly higher in WKY rats than in SHR, irrespective of the chronic treatment (2 weeks) with atorvastatin or elocalcitol ( Figure 1A ). Sildenafil (25 mg/kg; Figure 1B ) improved erectile responsiveness in all rat groups compared with untreated controls (P , .05; compare Figure 1A with B). However, erectile responsiveness, even in the presence of sildenafil, was still profoundly depressed in SHR compared with WKY rats (P , .05). At high stimulation frequencies (8-32 Hz), atorvastatin increased the sildenafil responsiveness in a dose-dependent manner. As shown in Figure 1B , the atorvastatin effects at doses of 30 mg/ kg were statistically significant at both 16 and 32 Hz (P , .05). Interestingly, at these frequencies, sildenafil responsiveness in SHR was not significantly different than that in WKY rats ( Figure 1B) . Conversely, elocalcitol dosing in SHR did not affect sildenafil responsiveness.
SHR showed lower cholesterol levels (76.9 6 8.8 mg/ dL; P , .05) and higher basal MAP levels (168 6 4.4 mm Hg; P , .001) than the WKY normotensive controls (108.9 6 9.1 mg/dL and 105 6 7.3 mm Hg, respectively). At the doses used, atorvastatin did not significantly affect either blood cholesterol levels (81.2 6 8.6 mg/dL at 5 mg/kg atorvastatin and 56.7 6 2.9 mg/ dL at 30 mg/kg) or basal MAP levels (160 6 8.3 mm Hg with 5 mg/kg atorvastatin and 161 6 5.7 mm Hg with 30 mg/kg) in SHR. No differences of calcemia values between WKY rats (9.42 6 0.20 mg/dL) and SHR (9.38 6 0.16 mg/dL) were observed, and no increase following elocalcitol treatment in SHR (9.68 6 0.13 mg/dL) was seen.
Gene Expression Analysis in Penile Tissue From Experimental Rats
Expression of RhoA and its downstream kinases (ROCK1 and ROCK2) in the different experimental groups, as evaluated by real-time quantitative reverse transcription (RT) PCR (qRT-PCR), is shown in Figure 2 . mRNA expression of RhoA, ROCK1, and ROCK2 was higher in CC samples from untreated SHR compared with WKY rats. Elocalcitol did not revert this overexpression. At both doses, atorvastatin treatment reduced RhoA gene expression (Figure 2A ), whereas ROCK1 mRNA was unaffected ( Figure 2B ). ROCK2 mRNA expression was inhibited by atorvastatin in a dose-dependent manner ( Figure 2C ). Atorvastatin-induced ROCK2 down-regulation resulted in statistically significance (P , .05) only at the highest dose tested (30 mg/kg; Figure 2C ). Other genes investigated, including nNOS, eNOS, and PDE5, were unaffected by hypertensive conditions or atorvastatin treatment (Table 1) .
Based on our previous observation that elocalcitol treatment down-regulates RhoA/ROCK overactivity in the bladder of SHR and reduces hypersensitivity to Y-27632 up to WKY levels (Morelli et al, 2007) , we studied the expression of the elocalcitol receptor, VDR, in the bladders and CC of these rat strains. Interestingly, VDR expression was approximately threefold higher in the bladder, but not in the CC, of SHR compared with WKY rats (Table 2) .
Effect of Atorvastatin and Elocalcitol on the RhoA/ROCK Pathway in hfPSMC
To further investigate atorvastatin effects on the RhoA/ ROCK pathway, we used a previously characterized SM cell preparation from hfPSMC (Granchi et al, 2002; Crescioli et al, 2003b; Filippi et al, 2003a,b; . Figure 3 shows the relative mRNA expression of RhoA and its associated kinases, ROCK1 and ROCK2, in hfPSMC and the distribution of these transcripts in several adult human tissues, including adult CC, as assessed by qRT-PCR. RhoA mRNA is abundantly expressed in all the tissues studied, and of the two RhoA-associated kinases, ROCK2 is the predominant isoform. Because hfPSMC express high levels of RhoA and its associated kinases, these cells represent a useful model to study the pharmacologic regulation of this protein family.
To study the effects of atorvastatin on RhoA membrane translocation, we used immunofluorescence confocal microscopy, as previously described (Morelli et al, 2007) . We monitored the intracellular localization of RhoA in hfPSMC under basal conditions ( Figure 4A ) and after a 48-hour stimulation with ET1 ( Figure 4D ), atorvastatin ( Figure 4G ), or ET1 and atorvastatin ( Figure 4L ). Pan-cadherin was used as a cell membrane marker ( Figure 4B , E, H, and M). ET1 increased RhoA localization at the plasma membrane, as evidenced by merging RhoA and pan-cadherin staining ( Figure 4F ). Atorvastatin alone ( Figure 4I ), and more impressively ; diagonally hatched bars, atorvastatin-treated SHR (5 mg/kg for 2 weeks); horizontally hatched bars, atorvastatintreated SHR (30 mg/kg for 2 weeks); and grey bars, elocalcitol-treated SHR (30 mg/kg for 2 weeks). Sildenafil increased erectile responses in all of the experimental groups (P , .05; data not shown) without changing the relative half-maximal response effective dose (ED 50 ) (shared ED 50 5 2.81 6 0.26 Hz; see text). *P , .05, **P , .01, and ***P , .001 vs untreated SHR. ns indicates not significant. after ET1 stimulation ( Figure 4N ), reduced membrane translocation of RhoA, as shown in the merged images of Figure 4 . To further validate these results, we studied by immunoblot the subcellular distribution of RhoA (membrane vs cytosol) and compared it with total RhoA. ET1 (100 nM) stimulated membrane expression of RhoA, which was reduced by atorvastatin (1 mM; Figure 5A , upper panel). Interestingly, atorvastatin treatment induced a robust RhoA accumulation in the cytosolic fraction ( Figure 5A , middle panel). Figure 5B shows the effect of atorvastatin, with or without the addition of GGPP, on membrane-bound RhoA in multiple experiments (n 5 3). As observed previously, atorvastatin (1 mM) significantly inhibited RhoA membrane translocation (P , .0001; Figure 5B ), whereas the addition of GGPP (1 mM), by restoring RhoA geranylgeranylation, reverted the atorvastatin effects (P , .01) and increased the quantity of membrane-bound RhoA over the control level (P , .05; Figure 5B ). Finally, to evaluate whether the activity of ROCK, the main kinase downstream of RhoA, was affected by atorvastatin treatment, we performed an immunokinase assay in hfPSMC ( Figure 5C-E) . In hfPSMC, ROCK activity was inhibited in time-and dose-dependent manners ( Figure 5C ) by the specific ROCK antagonist H-1152 (IC 50 5 7.5 6 0.4; n 5 2; Figure 5D ). Whereas ET1 (100 nM) stimulated a significant increase in ROCK activity (P , .05), atorvastatin (1 mM) completely prevented such an increase (n 5 3).
To investigate whether atorvastatin-induced reduction of RhoA membrane translocation affected RhoAmediated cellular functions, we studied the effect of increasing atorvastatin concentrations on cell migration and proliferation of hfPSMC stimulated by ET1 (100 nM) or PDGF-BB (25 ng/mL), respectively. ET1 induced a 238% 6 17% (P , .0001) increase in cell migration, and PDGF-BB increased cell proliferation by 168% 6 7% (P , .0001). Atorvastatin treatment resulted in dose-dependent inhibition of both cell migration and proliferation, with a similar IC 50 (shared IC 50 5 0.97 6 0.3 mM; Figure 6A ). Inhibition of hfPSMC cell growth and motility was also induced by another inhibitor of RhoA membrane translocation, elocalcitol ( Figure 6B ). Again, IC 50 s for elocalcitolinduced inhibitory effects were similar (shared IC 50 5 9.7 6 3 nM). Addition of increasing concentrations of GGPP (10 nM-1 mM) reversed atorvastatin-induced inhibition of migration in a dose-dependent manner ( Figure 6C) . Conversely, the maximal concentration of GGPP (1 mM) was unable to revert elocalcitol activity ( Figure 6C ). Blocking RhoA activation with C3 exoenzyme, through ADP ribosylation, induced an antiproliferative effect similar to that observed with atorvastatin ( Figure 6D ). Atorvastatin and C3 exoenzyme cotreatment did not enhance growth inhibition compared with either agent alone ( Figure 6D ). Blocking nitric oxide formation with the NOS inhibitor L-NAME (1 mM) or signaling with the guanylate cyclase inhibitor ODQ (1 mM) did not impair the antiproliferative action of atorvastatin ( Figure 5D) .
In hfPSMC cells, atorvastatin (1 mM for 48 hours) did not change RhoA or ROCK1 gene expression but significantly decreased ROCK2 mRNA ( Figure 7A-C) , as well as gene expression of RhoA/ROCK-dependent SM-related proteins such as desmin, a-SMA, SM22a, and myocardin ( Figure 7D-G) .
Discussion
In this study, we showed for the first time that atorvastatin, a widely prescribed antidyslipidemic drug, interferes with RhoA/ROCK signaling and restores sildenafil-induced penile erection in an animal model of chronic hypertension (SHR) up to the level of normotensive controls (WKY). This effect is most probably unrelated to the lipid-lowering activity of the statin because in our experimental model, atorvastatin did not significantly change blood cholesterol levels. Hence, other pleiotropic effects of atorvastatin, such as those of RhoA/ROCK activity and function (Bonetti et al, 2003; Rikitake et al, 2005) , could play a role.
Statins reduce cholesterol levels through a mevalonic acid-like moiety that competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), the ratelimiting step in cholesterol biosynthesis. However, independently of intracellular cholesterol biosynthesis, statins, through competition for HMG-CoA, also inhibit the formation of isoprenoid intermediates. These intermediates are essential for geranylgeranylation of small GTP-binding proteins, including RhoA, and for their binding to the plasma membrane, which is important for GDP-GTP exchange (Bonetti et al, 2003; Chrissobolis and Sobey, 2006) . In this study, we showed that in isolated hfPSMC (Granchi et al, 2002; Crescioli et al, 2003b; Filippi et al, 2003a,b; , atorvastatin decreases ET1-induced RhoA membrane translocation and therefore the downstream activation of ROCK and of the cascade leading to contractility, motility, proliferation, and SM differentiation. Accordingly, in isolated human penile cells, ET1-stimulated cell migration and PDGF-BB-induced cell proliferation were inhibited by atorvastatin in a dosedependent manner at submicromolar concentrations. In addition, gene expression of the predominant RhoAactivated kinase in erectile tissue, ROCK2, but not ROCK1, was inhibited in SHR, as well as in hfPSMC. Specific SM genes downstream of the RhoA/ROCK cascade, such as desmin, a-SMA, SM22a, and myocardin, were also inhibited by atorvastatin treatment. It has been previously demonstrated that overexpression of constitutively active RhoA stimulates transcription of multiple CArG-dependent SM genes (Mack et al, 2001; Gudi et al, 2002) , including desmin and a-SMA (Mericskay et al, 2000) , or their coactivators, such as myocardin (Wamhoff et al, 2004) , and that C3 exoenzyme, an inhibitor of RhoA activation, or Y-27632, an inhibitor of ROCK activity, counteracts this induction. Hence, our data indicated that atorvastatin can interact with the well-described ''excitation-contraction coupling'' mediated by the RhoA/ROCK pathway Table 1 . mRNA expression of eNOS, nNOS, and PDE5 in corpora cavernosa from experimental rats*3 eNOS nNOS PDE5 WKY3 2.8 6 0.40 (n 5 9) 3.1 6 0.56 (n 5 9) 1.9 6 0.14 (n 5 9) SHR3 2.4 6 0.40 (n 5 9) 3.9 6 0.60 (n 5 9) 1.8 6 0.23 (n 5 9) SHR+ atorvastatin (5 mg/kg) 2.5 6 0.40 (n 5 6) 2.8 6 0.69 (n 5 6) 1.6 6 0.18 (n 5 6) SHR+ atorvastatin (30 mg/kg) 3.0 6 0.20 (n 5 5) 2.5 6 0.34 (n 5 5) 1.6 6 0.16 (n 5 6) * Quantitative analysis, using real-time reverse transcription polymerase chain reaction, of eNOS, nNOS, and PDE5 mRNAs in corpora cavernosa samples from WKY and untreated and atorvastatin-treated SHR rats. Data were calculated by the comparative C t method and are expressed as mean 6 SEM of arbitrary units obtained by normalizing the mRNA expression of b2-microglobulin. No statistical differences among groups were found.
3 eNOS indicates endothelial nitric oxide synthase; n, number of analyzed samples; nNOS, neuronal nitric oxide synthase; PDE5, phosphodiesterase 5; SHR, spontaneously hypertensive rats; and WKY, Wistar-Kyoto. Table 2 . VDR mRNA expression in corpora cavernosa and bladder samples from WKY rats and SHR*3
Bladder
Corpora cavernosa WKY (n 5 9) SHR (n 5 9) WKY (n 5 11) SHR (n 5 11)
VDR3 mRNA, mean 6 SEM 3.34 6 0.82 8.39 6 1.284 2.60 6 0.37 3.68 6 0.60 * Quantitative analysis, using real-time reverse transcription polymerase chain reaction, of VDR mRNA in corpora cavernosa and bladder samples from WKY rats and SHR. Data were calculated by the comparative C t method and are expressed as mean 6 SEM of arbitrary units obtained by normalizing the mRNA expression of b2-microglobulin.
3 n, number of analyzed samples; SHR, spontaneously hypertensive rats; VDR, vitamin D receptor, and WKY, Wistar-Kyoto. 4 P , .01 vs any other group.
and interferes with the RhoA/ROCK-mediated ''excitation-transcription coupling'' that regulates SM cell commitment (Barlow et al, 2006; Posern and Treisman, 2006) . Statins are known to increase NO bioavailability through several mechanisms, including stabilization of eNOS mRNA (Laufs et al, 1997 (Laufs et al, , 1998 , increases in eNOS phosphorylation by protein kinase B (Kureishi et al, 2000) , or inhibition of caveolin 1 expression (Feron et al, 2001 ). Because we previously demonstrated that SM cells express a functional NOS (Filippi et al, 2003b) and that 2 distinct NO donors inhibit hfPSMC proliferation through cGMP formation (Filippi et al, 2003a) , we hypothesized that increased NO/cGMP availability contributed to the atorvastatin-induced antiproliferative effect. Our results indicates that inhibition of NO formation (L-NAME) or action (ODQ) fail to affect the antiproliferative effect of atorvastatin. In addition, studies in rat CC fail to support a modulation of atorvastatin on gene expression of enzymes involved in cGMP generation (NOS) or degradation (PDE5). Incubation with C3 exoenzyme mimicked atorvastatininduced growth arrest, further suggesting a direct effect of atorvastatin on RhoA activation, most probably by interfering with its geranylgeranylation. This view is supported by the observation that in the presence of GGPP, the effect of atorvastatin on RhoA membrane translocation and cell proliferation was completely reverted. In contrast, elocalcitol-induced growth arrest was not prevented by GGPP, suggesting that RhoA inhibition by this drug involves different mechanisms that remain to be investigated.
Our data confirm a previous observation of increased RhoA expression in penile tissue from SHR (Wilkes et al, 2004) and provide evidence that also the RhoA downstream kinases, ROCK1 and ROCK2, are upregulated in SHR CC, as previously reported in systemic vasculature (Mukai et al, 2001 ). Interestingly, chronic atorvastatin dosing, at both concentrations tested, decreased RhoA mRNA expression up to WKY levels. Because atorvastatin does not directly change RhoA gene expression in isolated penile SM cells, we hypothesized that the RhoA penile changes observed in vivo in SHR might be due to more complex and indirect interactions involving cGMP formation or degradation. However, as mentioned before, we could not find any alteration in the cGMP-related genes investigated, including NOS isoform expression and PDE5. Because atorvastatin also increases NOS signaling through posttranscriptional mechanisms (Laufs et al, 1997; Laufs et al, 1998; Kureishi et al, 2000; Feron et al, 2001) , it is still possible that RhoA down-regulation is cGMP mediated via NO release, as previously described Lee et al, 2004) . Accordingly, in the rat, an NO donor, NOR-1, and a ROCK inhibitor, Y-27632, synergize to induce in vivo penile erection (Mills et al, 2002) , and endothelium denudation decreases Y-27632-induced relaxation in isolated rabbit CC (Filippi et al, 2003a,b) .
In line with previous studies Ushiyama et al, 2004; Wilkes et al, 2004; Behr-Roussel et al, 2006; Jin and Burnett, 2006) , we found that erectile . Panel E shows ROCK activity (absorbance at 450 nm) in untreated (control) and ET1-treated (100 nM) cells with or without atorvastatin (1 mM). Results reported are mean 6 SEM of 3 independent experiments. *P , .05 vs any other treatments. function in SHR was strongly compromised and responsiveness to sildenafil, although present, was relatively limited and lower than in their normotensive counterpart WKY rats. A key result of this study is that atorvastatin ameliorates sildenafil-induced erections in a dose-dependent manner in SHR. In particular, atorvastatin restored sildenafil responsiveness up to WKY levels, at least at maximal stimulation frequencies (16-32 Hz). Conversely, atorvastatin was unable to affect the ICP:MAP ratio in SHR not supplemented with sildenafil.
Our results are also in line with recent preliminary observations in humans showing that atorvastatin might ameliorate nocturnal penile erection (Saltzman et al, 2004 ) and sildenafil responsiveness (Herrmann et al, 2006) in hypercholesterolemic patients with ED. Whether atorvastatin potentiation of sildenafil-induced erections in SHR is due to the above-described effects of the statin on the RhoA/ROCK pathway or involves positive effects on endothelial function and NO signaling (Bonetti et al, 2003; Rikitake et al, 2005) needs to be established.
It is interesting to note that elocalcitol, a vitamin D analog chemically unrelated to statins but known to negatively interfere with RhoA/ROCK in the bladder (Morelli et al, 2007) , was unable to restore sildenafil responsiveness in SHR. In addition, in isolated penile SM cells, elocalcitol inhibited cell migration and pro- Figure 6 . Effect of atorvastatin on migration and proliferation in human fetal penile smooth muscle cells (hfPSMC). Migration was induced by treatment with 100 nM endothelin 1 (ET1), proliferation was stimulated by 25 ng/mL platelet-derived growth factor BB (PDGF-BB). Upper panels show the dose-dependent inhibition of cell growth (closed circles) and migration (closed squares) induced by increasing concentrations of atorvastatin (10 nM-100 mM; panel A) or elocalcitol (10 pM-100 nM; panel B). ALLFIT analysis indicated that the half-maximal response inhibitory concentration values of atorvastatin (panel A) and elocalcitol (panel B) were not statistically different and could be fitted by the same equation. Data are expressed as percent variation (mean 6 SEM) over ET1-or PDGF-BB-induced migration or proliferation, respectively. Lower panels show the effects of different pharmacologic treatments on hfPSMC migration (panel C) and proliferation (panel D). Panel C shows the effect of ET1 (100 nM) alone or combined with atorvastatin (1 mM), geranylgeranyl pyrophosphate (10 nM-1 mM), and elocalcitol (10 nM) on cell migration. uP , .0005 and uuP , .00001 vs ET1.ˆP , .05 andˆˆP , .001 vs ET1 + atorvastatin. Panel D shows the effect of PDGF-BB (25 ng/mL) alone or combined with atorvastatin (1 mM), C3 exoenzyme (1 mg/mL), NG-nitro-L-arginine methyl ester (L-NAME) (1 mM), and 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (1 mM) on hfPSMC cell growth. uP , .0005 and uuP , .00001 vs PDGF-BB. Results are mean 6 SEM of at least 3 different experiments. Data are expressed as percent variation over basal conditions (control).
liferation at concentrations 3 log units higher than in other SM cells, such as those derived from prostate and bladder . A possible explanation for this lower sensitivity of penile musculature to elocalcitol, compared with other urinary tissues, is provided by the finding that in SHR, VDR expression is more abundant in the bladder than in the penis. Because elocalcitol actions are VDR mediated, this might explain why elocalcitol ameliorates bladder overactivity in SHR (Morelli et al, 2007) but not altered penile erections, as shown in the present study. Thus, the differential quantitative expression of VDR in bladder and CC suggests a plausible mechanism for the tissue-specific effect of elocalcitol on the RhoA/ROCK contractile pathway. Interestingly, elocalcitol has been reported to possess tissue-and cell-type selectivity in VDR activation, acting as a poor VDR agonist in tissues like intestine and kidney but as a potent VDR agonist in bone (Peleg et al, 2002 (Peleg et al, , 2003 . Our findings further extend the tissue selectivity of elocalcitol and show its ability to modulate RhoA/ROCK signaling only in defined target tissues. These cell context-selective actions, reported also for other VDR agonists (Ma et al, 2006) , translate into reduced induction of hypercalcemia and may account for the placebo-like side effect profile induced by elocalcitol treatment in patients (Colli et al, 2006) .
In conclusion, our data indicate that atorvastatin, but not elocalcitol, ameliorates sildenafil-induced penile erections in SHR, most probably by interfering with RhoA/ROCK signaling. This pleiotropic activity of atorvastatin, independent from the lipid-lowering one, might explain its positive effects in restoring erectile function and sildenafil responsiveness in ED patients (Saltzman et al, 2004; Herrmann et al, 2006) . Accordingly, a recent report indicates that atorvastatin can improve postoperative erectile function even in nonhypercholesterolemic patients undergoing radical retropubic prostatectomy (Hong et al, 2007) . 
